2018 News Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
12/12/18Anika to Showcase HYALOFAST at the International Cartilage Regeneration and Joint Preservation Society (ICRS) Focus Meeting in Milan
BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 12, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to showcase its entire Orthobiologics franchise, including HYALOFAST, at the upcoming ICRS Focus Meeting in Milan, Italy at the Humanitas Research University. The ICRS is the m... 
Printer Friendly Version
12/04/18Anika Resumes Global Distribution of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX
Company Expands HYALOFAST Commercial Reach in Asia, the Middle East and Latin America BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 4, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that it has resumed global distribution of its solid HA-based treatments, including HYALOFAST... 
Printer Friendly Version
10/24/18Anika Reports Third Quarter 2018 Financial Results
CINGAL Drives Strong International Viscosupplement Revenue Growth Achieves Solid Bottom Line Performance with $0.53 Diluted EPS BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 24, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today reported financial results for the third qua... 
Printer Friendly Version
10/24/18Susan Vogt Appointed to Board of Directors of Anika Therapeutics
Long-Serving Director Steven Wheeler to Retire from Board in February 2019 BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 24, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, announced that, effective immediately, Anika’s Board of Directors has appointed Susan Vogt a... 
Printer Friendly Version
10/10/18Anika to Issue Third-Quarter 2018 Financial Results and Business Highlights on Wednesday, October 24
BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 10, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2018 financial results after the close of the market on Wednesday, October 24, 2018 and hold its investor conference call on the same day, Wednesday, October 24, 2018, at 5:00 p.m. ET to discuss its financial results, business highlights, and outlook. The conference call can be ac... 
Printer Friendly Version
09/05/18Anika to Participate in the 2018 Morgan Stanley Global Healthcare Conference on September 12, 2018
BEDFORD, Mass.--(BUSINESS WIRE)--Sep. 5, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its President and Chief Executive Officer, Joseph Darling, and Chief Financial Officer, Sylvia Cheung, will participate in a fireside chat at the 2018 Morgan Stanley Global Healt... 
Printer Friendly Version
09/05/18Anika Appoints Dr. Cheryl Blanchard to Its Board of Directors
BEDFORD, Mass.--(BUSINESS WIRE)--Sep. 5, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer of Keratin Biosciences, Inc., has been appointed as a new independent member of the Company’s ... 
Printer Friendly Version
07/25/18Anika Reports Second Quarter 2018 Financial Results
Solid Top and Bottom Line Performance with 8% Product Revenue Growth and $0.68 Diluted EPS New Leadership Added to Optimize Commercial Reach and Operating Efficiency Multiple Initiatives Ongoing to Gain U.S. Regulatory Approval of CINGAL BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 25, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therap... 
Printer Friendly Version
07/11/18Anika to Issue Second-Quarter 2018 Financial Results and Business Highlights on Wednesday, July 25
BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 11, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2018 financial results after the close of the market on Wednesday, July 25, 2018 and to hold a conference call the next day, Thursday, July 26, 2018, at 9:00 a.m. ET to discuss its financial results, business highlights, and outlook. The conference call can be accessed by dialing 1-855-... 
Printer Friendly Version
06/19/18Anika Therapeutics Announces Top-Line Results from CINGAL 16-02 Clinical Trial in Knee Osteoarthritis
CINGAL 16-02 study did not achieve statistical significance at primary endpoint of 26 weeks in active comparator study; Company committed to working closely with regulators to gain U.S. approval Strong pain reduction and overall symptom relief consistent with statistically significant results of CINGAL 13-01 Phase III placebo-controlled clinical study BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 19, 2018-- Anika Therapeutics, Inc. (NAS... 
Printer Friendly Version
05/23/18Anika Therapeutics Announces $30 Million Accelerated Share Repurchase
BEDFORD, Mass.--(BUSINESS WIRE)--May 23, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that it will enter into an accelerated share repurchase (ASR) program to repurchase $30 million of its outstanding common stock. “Our ASR program reflects Anika’s strong finan... 
Printer Friendly Version
05/08/18Anika to Showcase Commercial and Pipeline Portfolio at 18th Bi-Annual European Society for Sports Traumatology, Knee Surgery and Arthroscopy Congress
BEDFORD, Mass.--(BUSINESS WIRE)--May 8, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced plans to showcase its innovative commercial and pipeline portfolio at the 18th bi-annual European Society for Sports Traumatology, Knee Surgery and Arthroscopy (ESSKA) Congress, being ... 
Printer Friendly Version
05/02/18Anika Reports First Quarter 2018 Financial Results
Successful Leadership Transition in Evolution to a Global Commercial Organization; MONOVISC and CINGAL Global Revenue Increased 38% Year-over-Year; Initiated Voluntary Recall of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX BEDFORD, Mass.--(BUSINESS WIRE)--May 2, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hya... 
Printer Friendly Version
04/24/18Anika to Present at the 2018 Deutsche Bank Health Care Conference on May 8, 2018
BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 24, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its President and Chief Executive Officer, Joseph Darling, will make a presentation at the 2018 Deutsche Bank Health Care Conference on Tuesday, May 8, 2018 at 8:40 am ET. The conference is being held... 
Printer Friendly Version
04/18/18Anika to Issue First-Quarter 2018 Financial Results and Business Highlights on Wednesday, May 2
BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 18, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2018 financial results after the close of the market on Wednesday, May 2, 2018 and to hold a conference call the next day, Thursday, May 3, 2018, at 9:00 a.m. ET to discuss its financial results, business highlights, and outlook. The conference call can be accessed by dialing 1-855-468-0... 
Printer Friendly Version
04/06/18Anika Announces Plans to Showcase HYALOFAST Hyaluronic Acid-Based Scaffold at the 2018 World Congress of the International Cartilage Repair Society
BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 6, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to showcase HYALOFAST®, a biodegradable, HA-based cartilage repair scaffold, at the 14th World Congress of the of the International Cartilage Repair Society (ICRS). The ICRS World Con... 
Printer Friendly Version
02/21/18Anika Reports Fourth Quarter and Full Year 2017 Financial Results
MONOVISC Global Revenue Increased 21% Year-over-Year for Fourth Quarter of 2017; Total Revenue Increased 10% for Full Year of 2017 BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 21, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today reported financial results for the fourth quarter and full year e... 
Printer Friendly Version
02/07/18Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21
BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 7, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2017 financial results after the close of the market on Wednesday, February 21, 2017 and to hold a conference call the next day, Thursday, February 22, 2018, at 9:00 a.m. ET to discuss its financial results, business highlights, and outlook. The conference call can be accessed by dialing... 
Printer Friendly Version
02/01/18Anika Therapeutics Announces Strategic Collaboration with the Institute of Integrative Biology at the University of Liverpool to Develop an Innovative Therapy for Osteoarthritis
BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced an agreement with the Institute of Integrative Biology at the University of Liverpool to collaborate on research to develop an injectable mesenchymal stem cell (MSC) therapy for the treatment of oste... 
Printer Friendly Version
01/24/18Anika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid Arthritis
BEDFORD, Mass.--(BUSINESS WIRE)--Jan. 24, 2018-- A new agreement to extend a two-year-long strategic collaboration that yielded a promising new modality for the treatment of rheumatoid arthritis (RA) was today announced by Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, and the Institute for Applied Life Sciences at ... 
Printer Friendly Version